Compare TRTX & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | IMMX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.2M | 716.2M |
| IPO Year | 2015 | 2021 |
| Metric | TRTX | IMMX |
|---|---|---|
| Price | $7.78 | $13.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.83 | ★ $19.20 |
| AVG Volume (30 Days) | 773.7K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $41.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.57 | $1.94 |
| 52 Week High | $9.85 | $15.10 |
| Indicator | TRTX | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 67.77 |
| Support Level | $7.57 | $7.96 |
| Resistance Level | $8.74 | $15.10 |
| Average True Range (ATR) | 0.12 | 0.78 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 51.28 | 72.82 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.